SG11202006435XA - Tricyclic compounds, compositions and medicinal applications thereof - Google Patents
Tricyclic compounds, compositions and medicinal applications thereofInfo
- Publication number
- SG11202006435XA SG11202006435XA SG11202006435XA SG11202006435XA SG11202006435XA SG 11202006435X A SG11202006435X A SG 11202006435XA SG 11202006435X A SG11202006435X A SG 11202006435XA SG 11202006435X A SG11202006435X A SG 11202006435XA SG 11202006435X A SG11202006435X A SG 11202006435XA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- tricyclic compounds
- medicinal applications
- medicinal
- applications
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201821000484 | 2018-01-04 | ||
| PCT/IN2019/050009 WO2019135259A1 (en) | 2018-01-04 | 2019-01-04 | Tricyclic compounds, compositions and medicinal applications thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006435XA true SG11202006435XA (en) | 2020-08-28 |
Family
ID=65033636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006435XA SG11202006435XA (en) | 2018-01-04 | 2019-01-04 | Tricyclic compounds, compositions and medicinal applications thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11407758B2 (en) |
| EP (1) | EP3735413B1 (en) |
| JP (1) | JP7361697B2 (en) |
| KR (1) | KR20200106176A (en) |
| CN (1) | CN111770926B (en) |
| AU (1) | AU2019205661B2 (en) |
| CA (1) | CA3087655A1 (en) |
| ES (1) | ES2928238T3 (en) |
| IL (1) | IL275817B2 (en) |
| SG (1) | SG11202006435XA (en) |
| WO (1) | WO2019135259A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200106176A (en) | 2018-01-04 | 2020-09-11 | 임페티스 바이오사이언시즈 엘티디. | Tricyclic compounds, compositions containing tricyclic compounds, and pharmaceutical uses thereof |
| TW202327612A (en) | 2021-09-10 | 2023-07-16 | 美商天恩治療有限公司 | Improved therapy with adenosine receptor antagonists |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0417790T3 (en) | 1989-09-14 | 1997-04-07 | Kyowa Hakko Kogyo Kk | S-triazolo (3,4-i) purine derivatives |
| CA2239881A1 (en) | 1996-10-07 | 1998-04-16 | Nobuo Kosaka | Condensed purine derivatives |
| US20010009180A1 (en) * | 1997-11-05 | 2001-07-26 | Hercules Inc. | Compositions and processes for increasing hot stock sizing effectiveness |
| CA2326716C (en) * | 1998-04-03 | 2006-12-12 | Otsuka Pharmaceutical Factory, Inc. | Triazolopurine derivative, pharmaceutical composition containing the derivative, adenosine a3 receptor ligand, and remedy for asthma |
| DE19826843A1 (en) | 1998-06-16 | 1999-12-23 | Boehringer Ingelheim Pharma | Novel imidazotriazolopyrimidines, process for their preparation and their use as medicaments |
| ES2166270B1 (en) | 1999-07-27 | 2003-04-01 | Almirall Prodesfarma Sa | DERIVATIVES OF 8-PHENYL-6,9-DIHIDRO- (1,2,4,) TRIAZOLO (3,4-I) PURIN-5-ONA. |
| WO2001058241A2 (en) | 2000-02-10 | 2001-08-16 | New York University | Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver |
| RU2315053C2 (en) * | 2000-05-26 | 2008-01-20 | Шеринг Корпорейшн | DERIVATIVES OF 5-AMINOPYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PYRIMIDINE, PHARMACEUTICAL COMPOSITION BASED ON THEREOF, USING AND METHODS FOR PREPARING INTERMEDIATE COMPOUNDS |
| CZ20031513A3 (en) * | 2000-12-01 | 2003-09-17 | Biogen, Inc. | Condensed purine derivatives functioning as A1 adenosine receptor antagonists |
| GB0100624D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
| UA80258C2 (en) | 2001-09-06 | 2007-09-10 | Biogen Inc | Methods of treating pulmonary disease |
| US20080194593A1 (en) | 2001-11-09 | 2008-08-14 | Rao Kalla | A2b adenosine receptor antagonists |
| DE60335294D1 (en) | 2002-12-19 | 2011-01-20 | Schering Corp | DLUNG OF EXTRAPYRAMIDAL SYNDROME |
| JP2005123160A (en) | 2003-09-22 | 2005-05-12 | Nissan Motor Co Ltd | Separator for fuel cell, fuel cell stack, method of manufacturing the separator, and fuel cell vehicle |
| CA2571242A1 (en) | 2004-06-17 | 2006-01-26 | The Regents Of The University Of California | Antagonizing an adenosine a2a receptor to amelioriate one or more components of addictive behavior |
| US7851478B2 (en) | 2005-06-07 | 2010-12-14 | Kyowa Hakko Kirin Co., Ltd. | Agent for preventing and/or treating movement disorder |
| CA2669166A1 (en) | 2006-11-09 | 2008-05-15 | Centre De Recherche Public De La Sante | Use of an adenosine antagonist |
| WO2009157938A1 (en) | 2008-06-26 | 2009-12-30 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists for treating cancer |
| AU2011306358B2 (en) * | 2010-09-24 | 2014-08-14 | Impetis Biosciences Ltd. | Fused tricyclic compounds as adenosine receptor antagonist |
| US9221821B2 (en) | 2012-06-05 | 2015-12-29 | Forest Laboratories Holdings, Limited | Methods for the synthesis of 1,3-substituted aminouracils and other xanthine-related compounds |
| KR20200106176A (en) | 2018-01-04 | 2020-09-11 | 임페티스 바이오사이언시즈 엘티디. | Tricyclic compounds, compositions containing tricyclic compounds, and pharmaceutical uses thereof |
-
2019
- 2019-01-04 KR KR1020207022497A patent/KR20200106176A/en not_active Application Discontinuation
- 2019-01-04 CN CN201980014800.XA patent/CN111770926B/en active Active
- 2019-01-04 US US16/959,543 patent/US11407758B2/en active Active
- 2019-01-04 EP EP19700850.1A patent/EP3735413B1/en active Active
- 2019-01-04 IL IL275817A patent/IL275817B2/en unknown
- 2019-01-04 JP JP2020537486A patent/JP7361697B2/en active Active
- 2019-01-04 WO PCT/IN2019/050009 patent/WO2019135259A1/en unknown
- 2019-01-04 AU AU2019205661A patent/AU2019205661B2/en active Active
- 2019-01-04 CA CA3087655A patent/CA3087655A1/en active Pending
- 2019-01-04 ES ES19700850T patent/ES2928238T3/en active Active
- 2019-01-04 SG SG11202006435XA patent/SG11202006435XA/en unknown
-
2022
- 2022-08-09 US US17/884,493 patent/US11981679B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3735413B1 (en) | 2022-07-06 |
| US20220402927A1 (en) | 2022-12-22 |
| CN111770926A (en) | 2020-10-13 |
| CN111770926B (en) | 2023-07-21 |
| ES2928238T3 (en) | 2022-11-16 |
| JP2021509905A (en) | 2021-04-08 |
| US11981679B2 (en) | 2024-05-14 |
| WO2019135259A1 (en) | 2019-07-11 |
| JP7361697B2 (en) | 2023-10-16 |
| IL275817B1 (en) | 2023-12-01 |
| AU2019205661B2 (en) | 2022-06-30 |
| CA3087655A1 (en) | 2019-07-11 |
| KR20200106176A (en) | 2020-09-11 |
| US20210070764A1 (en) | 2021-03-11 |
| AU2019205661A1 (en) | 2020-08-13 |
| IL275817B2 (en) | 2024-04-01 |
| IL275817A (en) | 2020-08-31 |
| EP3735413A1 (en) | 2020-11-11 |
| US11407758B2 (en) | 2022-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286693A (en) | Modulator compounds of the integrated stress pathway, compositions comprising same and uses thereof | |
| PL3407888T3 (en) | Pyridopyrroloquinoxaline compounds, their compositions and uses | |
| IL274297A (en) | Pyrazolo-piperidine substituted indole-2-carboxamides, compositions comprising same and uses thereof | |
| EP3466943A4 (en) | Diphenylaminopyrimidine and triazine compound, and pharmaceutical composition and use thereof | |
| ZA201804423B (en) | Antiproliferative compounds, and their pharmaceutical compositions and uses | |
| GB201712159D0 (en) | Pharmaceutical composition | |
| GB201804548D0 (en) | Pharmaceutical compositions | |
| GB201719447D0 (en) | Pharmaceutical composition | |
| IL275817A (en) | Tricyclic compounds, compositions and medicinal applications thereof | |
| EP3719010A4 (en) | Aromatic compound, pharmaceutical composition thereof and use thereof | |
| IL282950A (en) | Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof | |
| GB201807053D0 (en) | Pharmaceutical composition | |
| IL276783A (en) | Novel compound and pharmaceutical composition compirisng same | |
| SG11202103374TA (en) | Pharmaceutical composition | |
| GB201915828D0 (en) | Compounds, compositions and therapeutic uses thereof | |
| EP3727485C0 (en) | Pharmaceutical composition | |
| GB201808571D0 (en) | Pharmaceutical compositions | |
| IL282134A (en) | Aromatic compounds and pharmaceutical uses thereof | |
| IL276125A (en) | Dihydroindolizinone derivative compounds, compositions comprising same and uses thereof | |
| IL271513A (en) | Novel pharmaceutical composition | |
| GB201808567D0 (en) | Pharmaceutical compositions | |
| IL256252B (en) | Imidazodiazepine compound, compositions comprising the same and uses thereof | |
| ZA202006541B (en) | Pharmaceutical composition comprising brexpiprazole | |
| GB201808668D0 (en) | Compounds and compositions and uses thereof | |
| GB201915831D0 (en) | Compounds, compositions and therapeutic uses thereof |